Drug Type Small molecule drug |
Synonyms Anagliptin (JAN/INN), Beskoa, CWP-0403 + [4] |
Target |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (28 Sep 2012), |
Regulation- |
Molecular FormulaC19H25N7O2 |
InChIKeyLDXYBEHACFJIEL-HNNXBMFYSA-N |
CAS Registry739366-20-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09780 | Anagliptin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | JP | 28 Sep 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Noninsulin-Dependent, 2 | Phase 3 | KR | 01 May 2011 |
Phase 4 | 353 | dxtapgtlcw(cnfqbbyetd) = qmimwkkybc gepsvnbxsj (qontcbtsjh ) | - | 16 Nov 2019 | |||
Sitagliptin | dxtapgtlcw(cnfqbbyetd) = fjizgakxjv gepsvnbxsj (qontcbtsjh ) | ||||||
Phase 4 | 380 | gklbxhoytg(ivvhwynkoq) = popofbddop gncxdayhdm (atkwsmofpn ) View more | Positive | 12 Jun 2019 | |||
Sitagliptin | gklbxhoytg(ivvhwynkoq) = tsnktvdkfu gncxdayhdm (atkwsmofpn ) View more | ||||||
Phase 3 | 180 | wvidoxawcd(ztnzoflytf) = qhjgzmejgp xqccdcrani (zlnlywzwng, 0.70) | Non-inferior | 01 May 2015 | |||
sitagliptin | wvidoxawcd(ztnzoflytf) = wrpotjclmc xqccdcrani (zlnlywzwng, 0.61) |